Strategies for development of dengue virus inhibitors

Christian G. Noble, Yen Liang Chen, Hongping Dong, Feng Gu, Siew Pheng Lim, Wouter Schul, Qing Yin Wang, Pei-Yong Shi

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Antiviral drug discovery is becoming increasingly important due to the global threat of viral disease pandemics. Many members of the genus Flavivirus are significant human pathogens, among which dengue virus (DENV) alone poses a public health threat to 2.5 billion worldwide, leading to 50-100 million human infections each year. Neither vaccine nor effective therapeutics is currently available for DENV. Development of a DENV vaccine has been challenging, because of the need to simultaneously immunize and induce a long-lasting protection against all four serotypes of DENV; an incompletely immunized individual may be sensitized to life-threatening dengue hemorrhagic fever or dengue shock syndrome. The challenges associated with vaccine development have underscored the importance of development of antiviral therapies for DENV and other flaviviruses. Here we review the strategies to identify inhibitors for DENV therapy. Both viral and host proteins essential for viral replication cycle are potential targets for antiviral development. Inhibitors could be identified by multiple approaches, including enzyme-based screening, viral replication-based screening, structure-based rational design, virtual screening, and fragment-based screening. The strategies discussed in this report should be applicable to antiviral development of other viruses.

Original languageEnglish (US)
Pages (from-to)450-462
Number of pages13
JournalAntiviral Research
Volume85
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Dengue Virus
Antiviral Agents
Severe Dengue
Flavivirus
Dengue Vaccines
Vaccines
Viral Proteins
Pandemics
Virus Diseases
Drug Discovery
Therapeutics
Public Health
Viruses
Enzymes
Infection

Keywords

  • Antiviral
  • Cell-based assay
  • Dengue virus
  • Drug discovery
  • Enzyme assay
  • Flavivirus
  • High-throughput screening

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Noble, C. G., Chen, Y. L., Dong, H., Gu, F., Lim, S. P., Schul, W., ... Shi, P-Y. (2010). Strategies for development of dengue virus inhibitors. Antiviral Research, 85(3), 450-462. https://doi.org/10.1016/j.antiviral.2009.12.011

Strategies for development of dengue virus inhibitors. / Noble, Christian G.; Chen, Yen Liang; Dong, Hongping; Gu, Feng; Lim, Siew Pheng; Schul, Wouter; Wang, Qing Yin; Shi, Pei-Yong.

In: Antiviral Research, Vol. 85, No. 3, 03.2010, p. 450-462.

Research output: Contribution to journalArticle

Noble, CG, Chen, YL, Dong, H, Gu, F, Lim, SP, Schul, W, Wang, QY & Shi, P-Y 2010, 'Strategies for development of dengue virus inhibitors', Antiviral Research, vol. 85, no. 3, pp. 450-462. https://doi.org/10.1016/j.antiviral.2009.12.011
Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W et al. Strategies for development of dengue virus inhibitors. Antiviral Research. 2010 Mar;85(3):450-462. https://doi.org/10.1016/j.antiviral.2009.12.011
Noble, Christian G. ; Chen, Yen Liang ; Dong, Hongping ; Gu, Feng ; Lim, Siew Pheng ; Schul, Wouter ; Wang, Qing Yin ; Shi, Pei-Yong. / Strategies for development of dengue virus inhibitors. In: Antiviral Research. 2010 ; Vol. 85, No. 3. pp. 450-462.
@article{5c795ef98eec4b609d2701dc95d5e1fd,
title = "Strategies for development of dengue virus inhibitors",
abstract = "Antiviral drug discovery is becoming increasingly important due to the global threat of viral disease pandemics. Many members of the genus Flavivirus are significant human pathogens, among which dengue virus (DENV) alone poses a public health threat to 2.5 billion worldwide, leading to 50-100 million human infections each year. Neither vaccine nor effective therapeutics is currently available for DENV. Development of a DENV vaccine has been challenging, because of the need to simultaneously immunize and induce a long-lasting protection against all four serotypes of DENV; an incompletely immunized individual may be sensitized to life-threatening dengue hemorrhagic fever or dengue shock syndrome. The challenges associated with vaccine development have underscored the importance of development of antiviral therapies for DENV and other flaviviruses. Here we review the strategies to identify inhibitors for DENV therapy. Both viral and host proteins essential for viral replication cycle are potential targets for antiviral development. Inhibitors could be identified by multiple approaches, including enzyme-based screening, viral replication-based screening, structure-based rational design, virtual screening, and fragment-based screening. The strategies discussed in this report should be applicable to antiviral development of other viruses.",
keywords = "Antiviral, Cell-based assay, Dengue virus, Drug discovery, Enzyme assay, Flavivirus, High-throughput screening",
author = "Noble, {Christian G.} and Chen, {Yen Liang} and Hongping Dong and Feng Gu and Lim, {Siew Pheng} and Wouter Schul and Wang, {Qing Yin} and Pei-Yong Shi",
year = "2010",
month = "3",
doi = "10.1016/j.antiviral.2009.12.011",
language = "English (US)",
volume = "85",
pages = "450--462",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Strategies for development of dengue virus inhibitors

AU - Noble, Christian G.

AU - Chen, Yen Liang

AU - Dong, Hongping

AU - Gu, Feng

AU - Lim, Siew Pheng

AU - Schul, Wouter

AU - Wang, Qing Yin

AU - Shi, Pei-Yong

PY - 2010/3

Y1 - 2010/3

N2 - Antiviral drug discovery is becoming increasingly important due to the global threat of viral disease pandemics. Many members of the genus Flavivirus are significant human pathogens, among which dengue virus (DENV) alone poses a public health threat to 2.5 billion worldwide, leading to 50-100 million human infections each year. Neither vaccine nor effective therapeutics is currently available for DENV. Development of a DENV vaccine has been challenging, because of the need to simultaneously immunize and induce a long-lasting protection against all four serotypes of DENV; an incompletely immunized individual may be sensitized to life-threatening dengue hemorrhagic fever or dengue shock syndrome. The challenges associated with vaccine development have underscored the importance of development of antiviral therapies for DENV and other flaviviruses. Here we review the strategies to identify inhibitors for DENV therapy. Both viral and host proteins essential for viral replication cycle are potential targets for antiviral development. Inhibitors could be identified by multiple approaches, including enzyme-based screening, viral replication-based screening, structure-based rational design, virtual screening, and fragment-based screening. The strategies discussed in this report should be applicable to antiviral development of other viruses.

AB - Antiviral drug discovery is becoming increasingly important due to the global threat of viral disease pandemics. Many members of the genus Flavivirus are significant human pathogens, among which dengue virus (DENV) alone poses a public health threat to 2.5 billion worldwide, leading to 50-100 million human infections each year. Neither vaccine nor effective therapeutics is currently available for DENV. Development of a DENV vaccine has been challenging, because of the need to simultaneously immunize and induce a long-lasting protection against all four serotypes of DENV; an incompletely immunized individual may be sensitized to life-threatening dengue hemorrhagic fever or dengue shock syndrome. The challenges associated with vaccine development have underscored the importance of development of antiviral therapies for DENV and other flaviviruses. Here we review the strategies to identify inhibitors for DENV therapy. Both viral and host proteins essential for viral replication cycle are potential targets for antiviral development. Inhibitors could be identified by multiple approaches, including enzyme-based screening, viral replication-based screening, structure-based rational design, virtual screening, and fragment-based screening. The strategies discussed in this report should be applicable to antiviral development of other viruses.

KW - Antiviral

KW - Cell-based assay

KW - Dengue virus

KW - Drug discovery

KW - Enzyme assay

KW - Flavivirus

KW - High-throughput screening

UR - http://www.scopus.com/inward/record.url?scp=76949091459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76949091459&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2009.12.011

DO - 10.1016/j.antiviral.2009.12.011

M3 - Article

VL - 85

SP - 450

EP - 462

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -